Alpha-glucosidase inhibitor use is associated with decreased colorectal neoplasia risk in patients with type 2 diabetes mellitus receiving colonoscopy: a retrospective study

// Yohei Horibe 1 , Seiji Adachi 1 , Tomohiko Ohno 1 , Naoe Goto 1 , Mitsuru Okuno 1 , Midori Iwama 1 , Osamu Yamauchi 1 , Takao Kojima 1 , Koshiro Saito 1 , Takashi Ibuka 2, 3 , Ichiro Yasuda 2 , Hiroshi Araki 3 , Hisataka Moriwaki 3 and Masahito Shimizu 3 1 Department of Gastroenterology and Internal Medicine, Gihoku Kosei Hospital, Yamagata, 501-2105, Japan 2 Division for Regional Cancer Control, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan 3 Department of Gastroenterology and Internal Medicine, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan Correspondence to: Seiji Adachi, email: sadachi-gif@umin.ac.jp Keywords: type 2 diabetes mellitus, colorectal neoplasia, risk factor Received: October 13, 2016      Accepted: May 03, 2017      Published: June 08, 2017 ABSTRACT Purpose: The purpose of this study was to clarify the factors that influence the incidence of colorectal neoplasia in patients with type 2 diabetes mellitus (DM). Study Design and Setting: Among a total of 1176 patients who underwent total colonoscopy at our hospital, we retrospectively analyzed 168 patients with type 2 DM. Univariate and multivariate logistic regression analyses were then performed to identify the risk factors associated with colorectal neoplasia. Results: A multivariate analysis of these patients demonstrated that male gender (odds ratio [OR] = 4.04, 95% confidence interval [CI] = 1.67–10.37, p = 0.002), taking statins (OR = 4.59, 95% CI = 1.69–13.43, p = 0.003), taking alpha glucosidase inhibitor (α-GI) (OR = 0.35, 95% CI = 0.13–0.87, p = 0.023) and taking low-dose aspirin (LDA) (OR = 0.32, 95% CI = 0.10–0.95, p = 0.040) were independent factors associated with an increased (male gender and statins) or decreased (α-GI and LDA) risk of colorectal neoplasia. Conclusions: While male gender and taking statins are risk factors, taking α-GI as well as LDA may reduce the risk of colorectal neoplasia in patients with type2 DM.